Loading
Life sciences · Journal article
Diagnostics · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Pathological response after neoadjuvant therapy in breast cancer varies substantially across immunohistochemical surrogate subtypes. This study aimed to compare pretreatment biopsy features with post-treatment surgical pathology findings and to explore baseline predictors of favorable pathological response. Methods: We retrospectively analyzed female patients with invasive breast carcinoma treated with neoadjuvant therapy followed by surgery at a single institution between January 2020 and December 2024. Pretreatment histological features, stromal tumor-infiltrating lymphocytes, tumor cellularity, necrosis, in situ component, lymphovascular/perineural invasion, and immunohistochemical surrogate subtype were compared with post-treatment findings. Residual disease was assessed using the Residual Cancer Burden system, and vital status was analyzed as an exploratory outcome. Results: The analytical dataset included 146 breast carcinoma records. RCB-0, RCB-I, RCB-II, and RCB-III were observed in 20, 14, 64, and 46 of 144 evaluable records, respectively, and pCR was identified in 18/142 evaluable records. Tumor cellularity decreased significantly after therapy, whereas stromal TILs and tumor necrosis did not change significantly. Favorable pathological response and pCR were more frequent in HER2-positive and triple-negative tumors than in luminal tumors. In univariable Firth regression, higher baseline stromal TILs and HER2-positive/triple-negative subtype were associated with increased odds of RCB 0/I and pCR, and both associations persisted in multivariable models adjusted for age and grade. Nineteen patients (13.0%) deceased; crude mortality increased across RCB classes (0%, 14.3%, 7.8% and 26.1% for RCB-0 to RCB-III; p = 0.008), with no deaths among patients achieving pCR. Conclusions: In conclusion, favorable pathological response after neoadjuvant therapy was uncommon in this cohort and was observed mainly in HER2-positive and triple-negative tumors. Baseline stromal TILs and immunohistochemical surrogate subtype showed exploratory associations with response, supporting their further evaluation in larger, treatment-stratified cohorts with formal survival follow-up.